Compare TKO Group Holdings Inc (TKO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TKO Group Holdings Inc vs 10X Genomics Inc — how do they compare? TKO Group Holdings Inc trades at $181.02 (market cap $13.06B), while 10X Genomics Inc trades at $79.5 (market cap $9.92B). The key difference: TKO Group Holdings Inc is the larger of the two by market cap, and TKO Group Holdings Inc pays a 1.77% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TKO Group Holdings Inc for 30 Days and 10X Genomics Inc for 92 Days on average.
| TKO | TXG | |
|---|---|---|
Market Cap | $13.06B | $9.92B |
Volume | 999,906 | 9,372,166 |
Sector | Media | Health |
52-Week High | $224.96 | $97.74 |
52-Week Low | $175.58 | $11.48 |
Typical Hold Time | 30 Days | 92 Days |
Enterprise Value | $17.42B | $9.44B |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TKO trades at $178.64, down 1.24% on the day and near a 52-week low of $174.58 (Defense World, 2026-10-02). The stock is technically bearish with mixed earnings, missing Q2 2026 EPS estimates but beating Q1. Revenue growth is solid, with 2026 guidance raised to $5.3B, though high P/E of 62.68 signals premium valuation. A quarterly dividend of $0.79 was declared for September 2026.
Outlook is supported by strong analyst consensus (89% buy ratings) and a $227 price target, but risks include recent technical weakness, margin pressure, and competitive threats. The stock offers upside if media rights and live event execution drive earnings growth, yet volatility near lows warrants caution.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
